The major goals of the Synthetic Core Facility, which was renovated by the University of Arizona specifically for this Program Project Grant are to synthesize, purify and perform necessary analytical work on 75 mg to 10 g quantities of bioactive peptides, novel amino acids and peptide mimetics that are needed for the extensive biochemical, pharmacological, biophysical and biological studies which are part of this Program Project Grant. Of specific importance will be the development of proper asymmetric synthetic methodology, other synthetic methods, purification methods and analytical methods that are needed for the various research projects and protocols.
The Specific Aims are: 1) To develop and establish all necessary synthetic methodologies, purification protocols, and analytical procedures that are needed for preparing any ligands that are needed by investigators in the Program Project Grant;2) To prepare 0.20 g to 2 g of biphalin, novel dynorphin A fragments, novel bivalent ligands that are agonists at opioid receptors and antagonists at bradykinin and other CNS receptors for extensive in vitro and in vivo biological activity studies and for biophysical studies;3) To prepare by asymmetric synthesis quantities (1 g to 10 g) of novel amino acids and peptide mimetics that are needed for the preparation of ligands for the Program Project;4) To prepare up to gram quantities of potent bioactive peptides, glycopeptides, peptidomimetics, and peptide conjugates that will be needed for biological and/or biophysical studies;and 5) To prepare any other peptides, peptide mimetics or other ligands that are needed by investigators in this Program Project Grant for further biological and biophysical studies.
There are still many unmet public health needs in the treatment of pain and drug abuse in our society and worldwide. In this research we will examine the design, synthesis, and biological evaluation of novel peptide and peptidomimetic ligands for the treatment of prolonged pain, especially neuropathic pain that will address new mechanism of pain control with minimal side effects, drug seeking behavior and tolerance.
|Lee, Yeon Sun; Remesic, Michael; Ramos-Colon, Cyf et al. (2016) Cyclic non-opioid dynorphin A analogues for the bradykinin receptors. Bioorg Med Chem Lett 26:5513-5516|
|Deekonda, Srinivas; Rankin, David; Davis, Peg et al. (2016) Design synthesis and structure-activity relationship of 5-substituted (tetrahydronaphthalen-2yl)methyl with N-phenyl-N-(piperidin-2-yl)propionamide derivatives as opioid ligands. Bioorg Med Chem 24:85-91|
|Hall, Sara M; Lee, Yeon Sun; Hruby, Victor J (2016) Dynorphin A analogs for the treatment of chronic neuropathic pain. Future Med Chem 8:165-77|
|Deekonda, Srinivas; Cole, Jacob; Sunna, Sydney et al. (2016) Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations. Bioorg Med Chem Lett 26:222-7|
|Lee, Yeon Sun; Kupp, Robert; Remesic, Michael V et al. (2016) Various modifications of the amphipathic dynorphin A pharmacophore for rat brain bradykinin receptors. Chem Biol Drug Des 88:615-9|
|Nair, Padma; Yamamoto, Takashi; Cowell, Scott et al. (2015) Discovery of tripeptide-derived multifunctional ligands possessing delta/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities. Bioorg Med Chem Lett 25:3716-20|
|Cai, Minying; Marelli, Udaya Kiran; Bao, Jennifer et al. (2015) Systematic Backbone Conformational Constraints on a Cyclic Melanotropin Ligand Leads to Highly Selective Ligands for Multiple Melanocortin Receptors. J Med Chem 58:6359-67|
|Mehr-un-Nisa; Munawar, Munawar A; Lee, Yeon Sun et al. (2015) Design, synthesis, and biological evaluation of a series of bifunctional ligands of opioids/SSRIs. Bioorg Med Chem 23:1251-9|
|Giri, Aswini Kumar; Apostol, Christopher R; Wang, Yue et al. (2015) Discovery of Novel Multifunctional Ligands with Î¼/Î´ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain. J Med Chem 58:8573-83|
|Lee, Yeon Sun; Hall, Sara M; Ramos-Colon, Cyf et al. (2015) Blockade of non-opioid excitatory effects of spinal dynorphin A at bradykinin receptors. Receptors Clin Investig 2:|
Showing the most recent 10 out of 255 publications